Articles related to MENTAL HEALTH

The FDA’s guidance on psychedelic medicine is a landmark in mental health treatment. With the potential to treat PTSD, addiction, and treatment-resistant depression, psychedelics could heighten the field. However, the guidance also highlights the need for rigorous study of these substances, particularly regarding their subjective effects and the role of psychological support.

With catatonia’s prevalence estimates ranging from 9 to 30% in psychiatric emergency rooms and inpatient units, it’s crucial for healthcare professionals to be well-versed in its varied presentations and treatments.

The escalating crisis of burnout among oncology healthcare workers is a pressing issue that demands immediate attention. With up to 54% of doctors and nurses experiencing burnout, the need for systemic changes in the healthcare landscape has never been more urgent.

This systematic review illuminates the complex interplay between body dysmorphia, anabolic-androgenic steroid use, and mental health outcomes. It underscores the urgent need for effective interventions and treatments to address these interconnected issues.

The use of psychedelics in treating substance use disorder (SUD) is showing promise. A 2012 meta-analysis suggests a favorable probability of reduced alcohol use upon administration of LSD in a controlled context.

A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.